You are here

  • Home
  • Archive
  • Volume 11, Issue 1
  • Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement

Citation Tools

Article menu
XML
Cardiovascular medicine
Protocol
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Park H, Kang D, Ahn J, et al
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
BMJ Open 2021;11:e042587. doi: 10.1136/bmjopen-2020-042587